Developer docs
API playgroundTry for free, no card

Search company profiles

Stuart Therapeutics

Full company profile

uuid0002qka

Namestring
Stuart Therapeutics
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Stuart Therapeutics is a privately held biotechnology company founded in 2017 and headquartered in Stuart, United States. The company has developed PolyCol, a proprietary therapeutic platform focused on ophthalmic indications. The platform represents the core of Stuart Therapeutics' pipeline, addressing diseases of the eye through a targeted therapeutic approach.

The company operates with a small team of 1-10 employees and has assembled a leadership bench oriented around clinical and research execution. Eric Schlumpf serves as co-founder, President, and CEO; co-founder Shawn DeLorey leads Program Management and Corporate Development; Robert Baratta is Chairman, Chief Medical Officer, and Head of Product Development; Jodi Luchs serves as Chief Medical Officer; David Calkins is Chief Science Officer; Donald Stires is Chief Financial Officer; and Brian Del Buono serves as Executive Vice President of Research & Development. The presence of dual medical and scientific leadership roles indicates a focus on advancing programs from discovery through clinical development.

Stuart Therapeutics has raised $11,000,000 in a single disclosed funding round in March 2021, led by InFocus Capital Partners with participation from BioBrit, MiMo Capital, and the Wisconsin Alumni Research Foundation (WARF). The company operates as a pre-revenue clinical-stage biotech, and no commercial products, pricing models, partnership agreements, or revenue streams are disclosed in the available source data. Customer and revenue mechanics are not yet established, consistent with an early-stage therapeutic developer whose monetization pathway would typically involve licensing, partnership, or eventual commercialization.

Short descriptiontext

Stuart Therapeutics is a privately held, pre-revenue biotechnology company founded in 2017 that develops PolyCol, a proprietary therapeutic platform targeting ophthalmic indications, supported by a small clinical and research leadership team.

Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersStuart, United States
HQ citystring
Stuart
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
ophthalmic therapeutics, biopharmaceutical platform, protein therapeutics, eye disease treatment, collagen mimetic peptides
Industry3 codes
PRIMARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAK
Rare Ophthalmology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Ophthalmic Biopharmaceuticals
Social media profiles1 record
Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Stuart Therapeutics is a biotechnology company developing PolyCol, a proprietary therapeutic platform for ophthalmic (eye) indications. The company focuses on leveraging this platform to discover and advance drug candidates targeting ocular diseases. Operations are centered on preclinical and clinical-stage research for eye-related therapeutic products.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1PolyCol Therapeutic Platform
Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Ophthalmology-focused biopharmaceutical company developing therapeutics delivered via the suprachoroidal space for retinal and choroidal diseases, comparable as a small ophthalmology specialty developer with proprietary delivery technology.

TypeBroad incumbent
Description

Commercial-stage ophthalmology pharmaceutical company with approved glaucoma products and additional pipeline assets; broader in scale and commercialization stage, but directly comparable in therapeutic focus area.

TypeDirect peer
Description

Specialty ophthalmology pharmaceutical company developing therapeutics for ocular surface and retinal diseases, directly comparable as another focused ophthalmic therapeutics developer competing for similar indications and partnerships.

TypeEmerging player
Description

Clinical-stage gene therapy company focused on ophthalmic and cardiac diseases, comparable as a small platform-driven developer targeting inherited and age-related ocular disorders.

TypeDirect peer
Description

Ophthalmology specialty pharma developing therapies for retinal diseases and ocular surface conditions using proprietary drug delivery approaches; comparable platform-driven ophthalmic developer with both approved and pipeline assets.

TypeEmerging player
Description

Clinical-stage biotechnology company developing RNA-based therapeutics for genetic eye diseases and other conditions, providing comparability as an ophthalmology-focused developer using a novel therapeutic modality.

TypeDirect peer
Description

Clinical-stage biotechnology company developing novel treatments for inflammatory ocular diseases, providing a directly comparable ophthalmology-focused development model with platform technology across multiple indications.

TypeDirect peer
Description

Specialty pharmaceutical company focused on ophthalmic and retinal diseases using sustained-release drug delivery technologies, comparable as a focused ophthalmology therapeutic developer with approved products.

TypeBroad incumbent
Description

Clinical-stage biotechnology company with a leading ophthalmology gene therapy program (ABBVIE collaboration), comparable as a platform gene therapy developer whose ocular programs represent directly overlapping therapeutic targets.

TypeEmerging player
Description

Clinical-stage biotechnology company developing genetic therapies for rare ophthalmic diseases, comparable as a small-cap ophthalmology-focused developer with platform technology targeting multiple ocular indications.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Stuart Therapeutics

Ophthalmic Biopharmaceuticalsstuarttherapeutics.com

Stuart Therapeutics is a privately held, pre-revenue biotechnology company founded in 2017 that develops PolyCol, a proprietary therapeutic platform targeting ophthalmic indications, supported by a small clinical and research leadership team.

What Stuart Therapeutics does

Stuart Therapeutics is a privately held biotechnology company founded in 2017 and headquartered in Stuart, United States. The company has developed PolyCol, a proprietary therapeutic platform focused on ophthalmic indications. The platform represents the core of Stuart Therapeutics' pipeline, addressing diseases of the eye through a targeted therapeutic approach.

The company operates with a small team of 1-10 employees and has assembled a leadership bench oriented around clinical and research execution. Eric Schlumpf serves as co-founder, President, and CEO; co-founder Shawn DeLorey leads Program Management and Corporate Development; Robert Baratta is Chairman, Chief Medical Officer, and Head of Product Development; Jodi Luchs serves as Chief Medical Officer; David Calkins is Chief Science Officer; Donald Stires is Chief Financial Officer; and Brian Del Buono serves as Executive Vice President of Research & Development. The presence of dual medical and scientific leadership roles indicates a focus on advancing programs from discovery through clinical development.

Stuart Therapeutics has raised $11,000,000 in a single disclosed funding round in March 2021, led by InFocus Capital Partners with participation from BioBrit, MiMo Capital, and the Wisconsin Alumni Research Foundation (WARF). The company operates as a pre-revenue clinical-stage biotech, and no commercial products, pricing models, partnership agreements, or revenue streams are disclosed in the available source data. Customer and revenue mechanics are not yet established, consistent with an early-stage therapeutic developer whose monetization pathway would typically involve licensing, partnership, or eventual commercialization.

Stuart Therapeutics firmographics

Firmographics
Name
Stuart Therapeutics
Website
https://stuarttherapeutics.com
Company type
Private
Founded year
2017
Headcount range
11–50 employees
Short description
Stuart Therapeutics is a privately held, pre-revenue biotechnology company founded in 2017 that develops PolyCol, a proprietary therapeutic platform targeting ophthalmic indications, supported by a small clinical and research leadership team.
Ownership category
akta.pro rank

Stuart Therapeutics industry classification

Industry
Product category
Ophthalmic Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAK
Rare Ophthalmology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Ophthalmic therapeutics
  • Biopharmaceutical platform
  • Protein therapeutics
  • Eye disease treatment
  • Collagen mimetic peptides

Where Stuart Therapeutics is headquartered

Location

Headquarters

HQ city
Stuart
HQ country
United States
HQ region
North America

Markets served

Stuart Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others

Stuart Therapeutics product offering

Product offering

Core offering

Stuart Therapeutics is a biotechnology company developing PolyCol, a proprietary therapeutic platform for ophthalmic (eye) indications. The company focuses on leveraging this platform to discover and advance drug candidates targeting ocular diseases. Operations are centered on preclinical and clinical-stage research for eye-related therapeutic products.

Differentiator

Problem solved

Functional benefit

Products and services

  • PolyCol Therapeutic Platform

Companies that use Stuart Therapeutics

Customer profile

Ideal customer profiles1 record

Stuart Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Stuart Therapeutics partnerships and signals

Strategic signal

Recent moves3 records

Expansion highlights2 records

Stuart Therapeutics competitors and assessment

Company assessment

Direct peers

  • Clearside Biomedical: Ophthalmology-focused biopharmaceutical company developing therapeutics delivered via the suprachoroidal space for retinal and choroidal diseases, comparable as a small ophthalmology specialty developer with proprietary delivery technology.
  • Kala Pharmaceuticals: Specialty ophthalmology pharmaceutical company developing therapeutics for ocular surface and retinal diseases, directly comparable as another focused ophthalmic therapeutics developer competing for similar indications and partnerships.
  • Ocular Therapeutix: Ophthalmology specialty pharma developing therapies for retinal diseases and ocular surface conditions using proprietary drug delivery approaches; comparable platform-driven ophthalmic developer with both approved and pipeline assets.
  • Aldeyra Therapeutics: Clinical-stage biotechnology company developing novel treatments for inflammatory ocular diseases, providing a directly comparable ophthalmology-focused development model with platform technology across multiple indications.
  • EyePoint Pharmaceuticals: Specialty pharmaceutical company focused on ophthalmic and retinal diseases using sustained-release drug delivery technologies, comparable as a focused ophthalmology therapeutic developer with approved products.

Broad incumbents

  • Aerie Pharmaceuticals: Commercial-stage ophthalmology pharmaceutical company with approved glaucoma products and additional pipeline assets; broader in scale and commercialization stage, but directly comparable in therapeutic focus area.
  • REGENXBIO: Clinical-stage biotechnology company with a leading ophthalmology gene therapy program (ABBVIE collaboration), comparable as a platform gene therapy developer whose ocular programs represent directly overlapping therapeutic targets.

Emerging players

  • Lexeo Therapeutics: Clinical-stage gene therapy company focused on ophthalmic and cardiac diseases, comparable as a small platform-driven developer targeting inherited and age-related ocular disorders.
  • ProQR Therapeutics: Clinical-stage biotechnology company developing RNA-based therapeutics for genetic eye diseases and other conditions, providing comparability as an ophthalmology-focused developer using a novel therapeutic modality.
  • Applied Genetic Technologies Corporation: Clinical-stage biotechnology company developing genetic therapies for rare ophthalmic diseases, comparable as a small-cap ophthalmology-focused developer with platform technology targeting multiple ocular indications.

Market position

Strengths4 records

Weaknesses3 records

Competitive moat2 records

Key risks4 records

Key highlights4 records

Customer concentration

Stuart Therapeutics social profiles

Digital presence

Stuart Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Stuart Therapeutics leadership team

Management profile

Number of profiles

Profiles7 records

Stuart Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Stuart Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stuart Therapeutics

What does Stuart Therapeutics do?

Stuart Therapeutics is a biotechnology company developing PolyCol, a proprietary therapeutic platform for ophthalmic (eye) indications. The company focuses on leveraging this platform to discover and advance drug candidates targeting ocular diseases. Operations are centered on preclinical and clinical-stage research for eye-related therapeutic products.

When was Stuart Therapeutics founded?

Stuart Therapeutics was founded in 2017. It employs 11 to 50 people.

Where is Stuart Therapeutics based?

Stuart Therapeutics is headquartered in Stuart, United States, in the North America region.

Who are Stuart Therapeutics's main competitors?

Direct peers on record are Clearside Biomedical, Kala Pharmaceuticals, Ocular Therapeutix, Aldeyra Therapeutics and EyePoint Pharmaceuticals. Broad incumbents are Aerie Pharmaceuticals and REGENXBIO. Emerging players are Lexeo Therapeutics, ProQR Therapeutics and Applied Genetic Technologies Corporation.

Does Stuart Therapeutics have an API?

No public API is recorded for Stuart Therapeutics.

What industry is Stuart Therapeutics in?

Stuart Therapeutics's product category is Ophthalmic Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAK, Ophthalmology Specialty Pharmaceuticals, with a secondary code of HLAIAAAL, Ophthalmology Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogStuart Therapeutics Expands Pipeline with Corneal Wound Healing ProgramStuart Therapeutics submitted an investigational new drug application amendment to study its lead candidate ST-100 in corneal wound healing, marking its first expansion beyond dry eye disease. The proof-of-concept study will evaluate ST-100's ability to repair damaged helical collagen, with a phase 2 trial planned for the second half of 2027.Business Wire BlogStuart Therapeutics, Inc. to Present at the Citizens Private Ophthalmology SummitStuart Therapeutics CEO Eric Schlumpf will present at the Citizens Private Ophthalmology Summit on September 17, 2026. The company's lead asset ST-100, a collagen-reparative therapeutic for dry eye disease, has a Phase 3b trial planned for the first quarter of 2027.FinancialContent Business PageStuart Therapeutics, Inc. to Present at the Citizens Private Ophthalmology SummitStuart Therapeutics CEO Eric Schlumpf will present at the Citizens Private Ophthalmology Summit on September 17, 2026. The company's lead asset ST-100, a collagen-reparative therapeutic for dry eye disease, has a Phase 3b trial planned for the first quarter of 2027.FinancialContent Business PageStuart Therapeutics, Inc. Appoints Dave LeCause as Senior Commercial AdvisorStuart Therapeutics announced the appointment of Dave LeCause as senior commercial advisor, tasked with leading its commercial strategy as it advances ST-100, a collagen-reparative therapeutic for dry eye disease. LeCause brings over 30 years of eye care leadership, including vice president and general manager of Allergan's $2.5 billion eye care franchise. ST-100's Phase 3b trial is planned for the first quarter of 2027.BioSpaceStuart Therapeutics, Inc. Appoints Dave LeCause as Senior Commercial AdvisorStuart Therapeutics appointed Dave LeCause as senior commercial advisor to lead commercial strategy for its lead candidate ST-100 for dry eye disease. LeCause brings over 30 years of eye care leadership, including at Allergan. ST-100's Phase 3b trial is planned for the first quarter of 2027.FinancialContent Business PageArticles from Stuart Therapeutics, Inc.Stuart Therapeutics, Inc. has appointed David Jakeman as its new chief financial officer to oversee finance and accounting operations. Jakeman will support the company as it advances its lead candidate, ST-100 for dry eye disease, through its pending Phase 3b clinical trial toward commercialization.FinancialContent Business PageStuart Therapeutics, Inc. Appoints David Jakeman as Chief Financial OfficerStuart Therapeutics appointed David Jakeman as its new Chief Financial Officer to lead finance and accounting operations. Jakeman joins from Chimerix, where he helped build financial infrastructure leading to the company's acquisition by Jazz Pharmaceuticals. He will oversee financial strategy as Stuart advances its lead candidate ST-100 through Phase 3b trials.BioSpaceStuart Therapeutics, Inc. Appoints David Jakeman as Chief Financial OfficerStuart Therapeutics appointed David Jakeman as chief financial officer, bringing over 25 years of financial leadership experience. He will lead finance operations as the company advances its lead candidate ST-100 for dry eye disease through its pending Phase 3b trial. Jakeman previously held senior finance roles at Chimerix, which was acquired by Jazz Pharmaceuticals in 2025.PR NewswireStuart Therapeutics Announces Initial Results of Phase III Clinical Trial for ST-100 (Vezocolmitide) Ophthalmic Solution, a Novel Dry Eye Disease CandidateStuart Therapeutics announced initial results from its Phase III clinical trial of ST-100 (vezocolmitide) ophthalmic solution for Dry Eye Disease, which affects more than 30 million U.S. adults. While the primary endpoint measuring Schirmer's Responder Rate exceeded Phase II performance, it did not reach statistical significance; however, ST-100 demonstrated industry-leading secondary endpoint results, including statistically significant corneal staining improvement by Day 4 and visual function improvement by Day 2. The company plans to use these findings to design a second Phase III study and engage with the FDA to confirm the regulatory path to approval.PR NewswireStuart Therapeutics Announces the Appointment of Two New Board MembersStuart Therapeutics announced the appointment of Tracy Valorie and Jason Werner to its Board of Directors, bringing the total board members to five. Valorie brings 30 years of pharmaceutical and biotech experience, including senior roles at Bausch + Lomb and Pfizer, while Werner has led and sold ophthalmology companies including Eyevance to Santen Pharmaceuticals. The new directors are expected to guide the company through its next stage of development, with its lead asset ST-100 in Phase 3 clinical trials for an expected readout in Q1 2025.